Indivior Pharmaceuticals Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Indivior Pharmaceuticals de 12.9% y 2.8% respectivamente, mientras que el BPA crecerá en un 11.1% al año.
Información clave
12.9%
Tasa de crecimiento de los beneficios
11.12%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.4% |
| Tasa de crecimiento de los ingresos | 2.8% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 27 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
INDV: Raised Guidance And Buybacks Will Support A Turnaround Repricing
Analysts have lifted their price target for Indivior Pharmaceuticals from $50 to about $58, citing expectations for improved revenue growth, a slightly higher discount rate, adjusted profit margins, and a modestly higher future P/E multiple. These expectations are supported by recent research highlighting the company's turnaround plan and its focus on accelerating Sublocade and profitability.Indivior Pharmaceuticals (INDV) Stock Could Be 23% Undervalued As Cost Cut Narrative Builds
Indivior Pharmaceuticals (INDV) is back in focus after fresh attention on its role in treating opioid dependence, prompting investors to reassess the stock’s recent performance and current valuation based on publicly available financial metrics. See our latest analysis for Indivior Pharmaceuticals. The recent focus on Indivior Pharmaceuticals comes against a backdrop of steady gains, with a 30.72% 90 day share price return and a very strong 1 year total shareholder return of 175.54%,...Indivior: A Stronger Business Than When I First Covered It
Summary Indivior Pharmaceuticals (INDV) is focused on opioid addiction recovery, with SUBLOCADE as its flagship product. Sustained revenue from SUBLOCADE's monthly injection model differentiates INDV from generic addiction treatments. My previous Buy rating was based on the market undervaluing SUBLOCADE's earnings power and operational turnaround potential. The investment thesis has exceeded expectations, validating the strength of INDV's business model and product economics. Read the full article on Seeking AlphaIndivior: Trying To Break Addiction
Summary Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery. An analysis around INDV stock follows in the paragraphs below. Read the full article on Seeking AlphaIndivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025
Summary Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. Read the full article on Seeking AlphaIndivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback
Summary Indivior shares sold off on July 9th due to unexpected negative news from management, including the discontinuation of the schizophrenia drug Perseris and lower Sublocade guidance. Below, I argue why the market overreacted to Sublocade's lower FY24 guidance and why I expect Sublocade to continue growing. Current valuation indicates a FY24 EV/EBITDA multiple of sub 5x, offering an attractive entry point if Sublocade sales prove to be robust in the long term. Confidence in Sublocade was signalled by the board's approval of an "accelerated" $100 million repurchase program, which represents 6% of outstanding shares at the current share price of $12.5. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 1,374 | 517 | 538 | 555 | 4 |
| 12/31/2027 | 1,308 | 473 | 485 | 381 | 5 |
| 12/31/2026 | 1,258 | 414 | 360 | 305 | 5 |
| 3/31/2026 | 1,290 | 252 | -193 | -111 | N/A |
| 12/31/2025 | 1,239 | 210 | -94 | -27 | N/A |
| 9/30/2025 | 1,181 | 128 | 117 | 177 | N/A |
| 6/30/2025 | 1,173 | 108 | 171 | 218 | N/A |
| 3/31/2025 | 1,170 | -7 | 115 | 148 | N/A |
| 12/31/2024 | 1,188 | 7 | 5 | 36 | N/A |
| 9/30/2024 | 1,182 | -91 | -245 | -213 | N/A |
| 6/30/2024 | 1,147 | -248 | -247 | -194 | N/A |
| 3/31/2024 | 1,124 | -112 | -351 | -301 | N/A |
| 12/31/2023 | 1,093 | -126 | -353 | -300 | N/A |
| 9/30/2023 | 1,042 | -235 | -89 | -52 | N/A |
| 6/30/2023 | 1,002 | -59 | -22 | -11 | N/A |
| 3/31/2023 | 947 | -50 | 23 | 35 | N/A |
| 12/31/2022 | 901 | -44 | -9 | -4 | N/A |
| 9/30/2022 | 882 | 166 | 176 | 181 | N/A |
| 6/30/2022 | 838 | 152 | 160 | 145 | N/A |
| 3/31/2022 | 818 | 166 | 175 | 189 | N/A |
| 12/31/2021 | 791 | 205 | 339 | 353 | N/A |
| 9/30/2021 | 753 | 156 | 101 | 115 | N/A |
| 6/30/2021 | 725 | 139 | 81 | 115 | N/A |
| 3/31/2021 | 674 | 95 | 39 | 42 | N/A |
| 12/31/2020 | 647 | -148 | -197 | -193 | N/A |
| 9/30/2020 | 595 | -190 | -84 | -82 | N/A |
| 6/30/2020 | 634 | -152 | -70 | -69 | N/A |
| 3/31/2020 | 700 | -95 | -131 | -130 | N/A |
| 12/31/2019 | 785 | 134 | N/A | 151 | N/A |
| 9/30/2019 | 889 | 213 | N/A | 200 | N/A |
| 6/30/2019 | 935 | 254 | N/A | 275 | N/A |
| 3/31/2019 | 988 | 248 | N/A | 413 | N/A |
| 12/31/2018 | 1,005 | 275 | N/A | 303 | N/A |
| 9/30/2018 | 1,033 | 106 | N/A | 276 | N/A |
| 6/30/2018 | 1,064 | 67 | N/A | 210 | N/A |
| 3/31/2018 | 1,083 | 71 | N/A | 260 | N/A |
| 12/31/2017 | 1,093 | 58 | N/A | 295 | N/A |
| 9/30/2017 | 1,087 | 281 | N/A | 360 | N/A |
| 6/30/2017 | 1,080 | 81 | N/A | 409 | N/A |
| 3/31/2017 | 1,065 | 65 | N/A | 370 | N/A |
| 12/31/2016 | 1,058 | 35 | N/A | 407 | N/A |
| 9/30/2016 | 1,047 | -6 | N/A | 326 | N/A |
| 6/30/2016 | 1,028 | 191 | N/A | 283 | N/A |
| 3/31/2016 | 1,021 | 201 | N/A | 252 | N/A |
| 12/31/2015 | 1,014 | 228 | N/A | 320 | N/A |
| 9/30/2015 | 1,037 | 268 | N/A | 300 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.9% al año) de INDV es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (12.9% al año) de INDV crezcan menos que el mercado US (18.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de INDV crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (2.8% al año) de INDV crezcan más despacio que el mercado de US (12.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 2.8% al año) de INDV crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de INDV se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/05 22:56 |
| Precio de las acciones al final del día | 2026/07/02 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Indivior Pharmaceuticals, Inc. está cubierta por 10 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Glen Santangelo | Barclays |
| Graham Glyn Parry | BofA Global Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |